Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 3/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | DCLRE1B | Q9H816 | 3/20 | 0.52 |
| ▸ | DCLRE1A | Q6PJP8 | 1/20 | 0.52 |
| ▸ | KDM4A | O75164 | 1/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | HNF4A | P41235 | 1/20 | 0.43 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 2/20 | 0.41 |
| ▸ | ACACA | Q13085 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28425305 | 0.85 | HDAC1 (0.53) | ACLYHDAC1KDM4AKCNA5CTSS | |
| SCHEMBL8175623 | 0.85 | HDAC1 (0.55) | HDAC1KDM4AKCNA5CTSSCTSK | |
| SCHEMBL16790458 | 0.84 | EPHX2 (0.48) | ACLYHDAC1KDM4AKCNA5EPHX2 | |
| SCHEMBL1808874 | 0.84 | KCNA5 (0.56) | HDAC1KDM4AKCNA5CTSSCTSK | |
| SCHEMBL8184051 | 0.84 | HDAC1 (0.52) | HDAC1KDM4AKCNA5CTSSCTSK | |
| SCHEMBL28646590 | 0.83 | HDAC1 (0.59) | HDAC1KDM4AKCNA5CTSSCTSK | |
| SCHEMBL26659635 | 0.82 | KCNA5 (0.55) | HDAC1KDM4AKCNA5CTSSCTSK | |
| SCHEMBL16635222 | 0.82 | PPARD (0.42) | ACLYHDAC1 | |
| SCHEMBL23979460 | 0.82 | IDO1 (0.47) | ACLYKDM4AKCNA5 | |
| SCHEMBL28215080 | 0.82 | KDM4A (0.42) | HDAC1DCLRE1BKDM4AKCNA5CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361663-B2 | N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa | AVENTIS PHARMACEUTICALS INC. (US) | 2008-04-22 | — | — | US | disclosed |
| EP-1263726-B1 | N-ACYLPYRROLIDIN-2-YLALKYLBENZAMIDINE DERIVATIVES AS INHIBITORS OF FACTOR XA | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-09-26 | — | — | EP | disclosed |
| US-20040087570-A1 | N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-05-06 | — | — | US | disclosed |
| US-20030092698-A1 | N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa | AVENTIS PHARMACEUTICALS INC. | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092698-A1 | N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa | TFPI, SERPINC1, HABP2 | ACLY 1861/4885HDAC1 897/4885DCLRE1B 1616/4885 |
| US-20040087570-A1 | N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa | TFPI, SERPINC1, HABP2 | ACLY 1861/4885HDAC1 897/4885DCLRE1B 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.